Best Immunology Companies in Germany
The 45 best Immunology companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BioNTech.
- Immunology Market size is set to grow by USD 56.07 billion from 2022 t
Ranked: Best Immunology companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BioNTech Developer of immunotherapeutics for the treatment of cancer and other diseases 78Patents top 7%Innovation top 17%News top 26%Tech top 28% All 13 signals ▾Patentstop 7% Innovationtop 17% Newstop 26% Techtop 28% Globaltop 28% Fundingtop 29% Talenttop 29% Growthtop 33% Moattop 35% Producttop 39% Markettop 48% Partnersbottom 43% Fin. healthbottom 42% Patents: 2,228 patents matched (strict assignee match) · 1521 filings since 2022 vs 431 in 2017-21 Innovation: 2,228 patents (top 1% of patent-holders) · 1521 filings since 2022 vs 431 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $806M | 52 mo ago | 4,530 4,530 → 5,204 (+15%) | 2008 | Christoph Huber Co-Founder & Managing Director | TurbopackSentryNode.js+19 | 2,227 patents mRNA vaccine formulation and delivery, nucleic‑acid therapeutics, cancer immunotherapy antibodies | 1 partnership |
| 2 | SciRhom Developer of drugs for treating autoimmune disease 40Moat top 31%Patents top 32%Funding top 34%Talent top 38% All 8 signals ▾Moattop 31% Patentstop 32% Fundingtop 34% Talenttop 38% Innovationtop 41% Globalbottom 44% Marketbottom 30% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · IP moat: 29 patents Patents: 29 patents matched (strict assignee match) · 23 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $79M | 25 mo ago | 12 | 2016 | Matthias Schneider Co-Founder & CSO | — | 29 patents Humanized therapeutic antibodies and protein inhibitors targeting iRhom2 for disease treatment | — |
| 3 | Cellzome Small-molecule kinase targeted drugs to treat inflammatory diseases | $78M | 212 mo ago | 90 | 2000 | — | — | 201 patents Enzyme‑focused small‑molecule drug discovery and target‑validation platforms | — |
| 4 | SuppreMol Developer of therapeutics for the treatment of autoimmune diseases | $71M | 159 mo ago | 50 | 2002 | Jose Almeida CEO | — | 185 patents Therapeutic antibodies and soluble Fc‑receptor formulations for immune modulation | — |
| 5 | Topas Therapeutics Developer of nanoparticle-based therapeutics for immunology disorders | $69M | 60 mo ago | 14 14 → 21 (+50%) | 2016 | — | WordPressMySQLPHP+7 | 54 patents Targeted antigen delivery via amphiphilic polymer‑based nanoparticle vaccine platforms | — |
| 6 | InflaRx Developer of antibody therapeutics for inflammatory and immune diseases | $64M | 106 mo ago | 56 56 → 47 (-16%) | 2008 | Renfeng Guo Co-Founder | OpenSSLBootstrapApache HTTP Server+10 | 152 patents C5a complement receptor antagonists and related small‑molecule therapeutics. | — |
| 7 | Cardion Specializes in development of novel heart disease and cell transplantation therapies | $46M | 287 mo ago | — | 1996 | Jurgen Schrader Founder | — | — | — |
| 8 | sterna biologicals Developer of an antisense molecule for treating chronic inflammatory diseases | $27M | 67 mo ago | 10 | 2006 | — | — | 72 patents DNAzyme hydrogel therapeutics and molecular diagnostics for ulcerative colitis | — |
| 9 | Dolthera Small molecule therapeutics for inflammatory diseases. | $25M | 214 mo ago | — | — | — | — | — | — |
| 10 | Phenex Pharma Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune… | $24M | 191 mo ago | 21 | 2002 | Claus Kremoser CEO | — | — | — |
| 11 | Lophius Biosciences Develops T-cell-based diagnostics for infectious and immune diseases | $24M | 83 mo ago | 28 | 2008 | — | — | 44 patents PCR-based immunodiagnostic assays for T‑cell monitoring and tuberculosis detection | — |
| 12 | Protagen Diagnostics for Personalized Medicine in Autoimmune diseases using autoantibody based biomarkers | $20M | 140 mo ago | 20 | 1997 | — | — | 166 patents Molecular diagnostic biomarkers for autoimmune diseases and melanoma immunotherapy detection. | — |
| 13 | AdvanceCOR Developer of drugs and diagnostics for cardiovascular diseases | $11M | 74 mo ago | 16 | 2012 | Gotz Munch Co-Founder & Managing Director | — | 44 patents Cyclic peptide therapeutics targeting autoimmune and thyroid disorders | — |
| 14 | ActiTrexx Provider and developer of cellular therapy agents for stem cell transplantation patients | $4M | 65 mo ago | 11 | 2020 | Andrea Tüttenberg Tuttenberg Co-Founder & CEO | — | — | — |
| 15 | Protectimmun Treatments for prevention and therapy of allergic and chronic inflammatory diseases | $2M | 183 mo ago | — | 2007 | Otto Holst Co-Founder | — | 17 patents Plant-derived polysaccharide and probiotic formulations for allergy and inflammatory disease therapeutics | — |
| 16 | T-Cell Europe Cell-based therapies for kidney transplants patients. | $2M | 171 mo ago | 2 | 2010 | — | — | — | — |
| 17 | Phialogics Developer of cell therapies for the treatment of auto-immune diseases | $657K | 40 mo ago | 5 | 2021 | Andreas Knethen Co-Founder | — | — | — |
Top 12 Immunology companies in Germany
#1
Series A · Planegg, Bavaria · founded 2016 · 12 employees$79Mraised▾
Developer of drugs for treating autoimmune disease. The product provided inhibits TACE (TNF-alpha converting enzyme or ADAM17) is an essential regulator of signaling pathways, including TNF-alpha and EGFR (epidermal growth factor receptor) signaling. The TACE-dependent release of TNF-alpha and other pro-inflammatory mediators from immune cells is regulated by iRhom2 (RHBDF2, Rhomboid family member 2, refs. 5-7) provided a way to target the pro-inflammatory activities of TACE.
- Jul 2024Series A$70M
- Nov 2021Seed$9M
- Oct 2016Seed—
#2
Public · Mainz, Rhineland-Palatinate · founded 2008 · 4530 employees$806Mraised▾
Developer of immunotherapeutics for the treatment of cancer and other diseases. Its oncology drug pipeline contains several classes of drugs which include mRNA treatments, modified cell therapies, antibodies, and small molecule immunomodulators that have been optimised for distinct modes of action, high precision targeting, potency, and efficacy.
- Apr 2022Post IPO$150M
- Sep 2020Post IPO$444.8M
- Jun 2020Post IPO$250M
- Mar 2020Post IPO$133.3M
#3
Series B · Hamburg, Hamburg · founded 2016 · 14 employees$68.5Mraised▾
Developer of nanoparticle-based therapeutics for immunology disorders. The company's pipeline drug candidates include TPM 203 for pemphigus Vulgaris, TPM 501/502 for celiac disease, and anti-drug immune response.
- Jul 2021Series B$21.3M
- Mar 2021Grant (prize money)$492.1K
- Oct 2020Series B$25.8M
- Apr 2020Grant (prize money)$290.8K
#4
Series A · Marburg, State of Hessen · founded 2006 · 10 employees$27.1Mraised▾
Sterna Biologicals has developed a therapeutic antisense molecule for treating chronic inflammatory diseases. The company has developed hgd40, a DNAzyme which acts as an antisense molecule by targetting the key transcription factor involved in regulating type-2 inflammation. The molecule is used to treat chronic diseases such as asthma, COPD, atopic dermatitis, and ulcerative colitis.
- Jan 2021Series A$12.3M
- Apr 2020Series A$13.1M
#5
Seed · Frankfurt Am Main, Hesse · founded 2021 · 5 employees$657.4Kraised▾
Developer of cell therapies for the treatment of auto-immune diseases. The company is developing cell-type-specific immune checkpoint activators by using protein engineering of receptor ligands to generate signaling agonists that modulate the activity of immune cells.
- Apr 2023Seed$657.4K
#6
Acquired · Planegg, Bavaria · founded 2002 · 50 employees$71Mraised▾
Developer of therapeutics for the treatment of autoimmune diseases. The company's lead candidate is "SM101, a Novel Recombinant, Soluble, Human FcyIIB Receptor, for the Treatment of systemic lupus erythematosus. Also, it develops a pipeline for primary immune thrombocytopenia (ITP), rheumatoid arthritis (RA), and other autoimmune conditions.
- May 2013Series D$20.6M
- Dec 2010Series C$20.2M
- Jul 2008Series B$25M
- May 2006Series A$5.2M
#7
Acquired · Heidelberg, Baden-wurttemberg · founded 2000 · 90 employees$78.1Mraised▾
Cellzome is a drug discovery company focussed on developing a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline small-molecule therapeutics is based on Kinobeads, a proprietary technology for screening and profiling kinases in relevant cells and tissues. Its small molecules target inflammatory mediators such as PI3Kg and Zap-70, Jak3 and mTOR and have a potential to be oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. It was acquired by GSK for $99M in May 2012.
- Dec 2008Grant (prize money)$4.9M
- Mar 2003Series C$47.1M
- Mar 2001Series B$31M
#8
Public · Jena, Thuringia · founded 2008 · 56 employees$64.1Mraised▾
Developer of antibody therapeutics for inflammatory and immune diseases. The company focuses on the development of monoclonal antibodies that target activation products of the complement system for application in inflammatory diseases. The product pipeline inlcudes Vilobelimab for oncology, immuno-dermatology, and inflammatory diseases, and IFX002 C5a Inhibitor for chronic inflammatory and autoimmune diseases.
- Oct 2017Series D$30M
- Jul 2016Series C$34.1M
- Jul 2014Series B—
- Mar 2009Series A—
#9
Series B · Regensburg, Bavaria · founded 2008 · 28 employees$23.7Mraised▾
Develops T-cell-based diagnostics for infectious and immune diseases. It has two proprietary platforms, T-activation Technology which allows the detection of clinically relevant effector cells such as T helper, NK, NKT-like, and CTL cells,and Reverse T cell Technology (RTT) which detects pathogen-specific activated T-cells. The company has two diagnostic kits on the market based on their proprietary platform. T-TRACK CMV for the HLA-independent detection of CMV-specific cell-mediated immunity, and T-TRACK IMMUNOSCAN to check immune response due to natural, induced immunomodulation, In addition, Lophius also provides services and T-cell-based research tools for researchers and biopharma companies.
#10
Series A · Planegg, Bavaria · founded 2012 · 16 employees$11Mraised▾
Developer of drugs and diagnostics for cardiovascular diseases. The company's lead candidate is "Revacept", a therapeutic agent used to prevent and treat acute arterial thrombosis that can lead to heart attack and stroke. Also, it is developing GPVI-inhibiting antibodies to inhibit the attachment of platelets to the wall of a blood vessel.
- Jun 2020Series A—
- May 2016Grant (prize money)—
- 2015Series A$2.5M
- Apr 2013Series A$8.5M
#11
Deadpooled · Erkrath, North Rhine Westphalia · founded 1996$46.3Mraised▾
Cardion was a biopharma company which was developing cell and gene therapy treatments for cardiovascular diseases , autoimmune diseases. Their lead candidate was NOStentin, a non-viral, local gene therapeutic which was targeted to prevent restenosis, one of the most significant complications in interventional cardiology. The company was closed down post the sale of human interleukin IL-15 cytokine receptor blocker (CRB-15) to Roche in 2004.
- Sep 2002Series C$11.3M
- Dec 2000Series C$35M
#12
Acqui-Hired · Dortmund, North Rhine Westphalia · founded 1997 · 20 employees$19.8Mraised▾
Protagen is a provider of services, products and software solutions for protein research. Protagen provides products and GMP compliant services. The patented platform of protein expression libraries UNIclone allows Protagen the development of a new class of diagnostics based on autoantibody signatures in blood. Utilizing a personalized medicine approach, their multi-marker assay technology SeroTag; enables differential diagnosis and patient stratification for Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis and others. Protagen launched a research test in July 2014 for Systemic Sclerosis, secured by strong IP coverage and validated by proof-of concept studies in thousands of clinical samples.
- Dec 2014Series D—
- Sep 2010Series D$12.9M
- Aug 2008Series C—
- Jan 2008Series C$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Germany
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,045 Germany-affiliated papers.
- Heidelberg University290
- German Cancer Research Center198
- Charité - Universitätsmedizin Berlin148
- Ludwig-Maximilians-Universität München123
- University Hospital Heidelberg96
- Immune system13→187
- T cell2→64
- Cancer5→55
- Cancer research19→68
- Tumor microenvironment1→50
- Immune system18→298
- Oncology16→105
- Internal medicine24→101
- Cancer7→84
- Disease3→62
- Immune system1→99
- Disease1→52
- Cancer4→38
- Tumor microenvironment2→29
- Internal medicine4→31
Where immunology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in Germany
Germany immunology patent filing is cooling — 3,857 filings from 703 assignees (2016–2025), led by Immatics Biotechnologies, TRON Translationale Onkologie AN, Biontech SE; annual filings 201→144.
- Immatics Biotechnologies3119
- TRON Translationale Onkologie AN95
- Biontech SE87
- Biontech RNA Pharmaceuticals73
- Singh Harpreet54
- Weinschenk TONI53
- Fritsche JENS53
- Merck Patent45
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.